Wenqing Yao
Qingdao University of Science and Technology(CN)Wilmington University(US)Sichuan University(CN)West China Hospital of Sichuan University(CN)State Key Laboratory of Chemical Engineering(CN)First Affiliated Hospital of Zhengzhou University(CN)Incyte (United States)(US)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Epigenetics and DNA Methylation, Lymphoma Diagnosis and Treatment, Peptidase Inhibition and Analysis, Histone Deacetylase Inhibitors Research
Most-Cited Works
- → Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer(2006)375 cited
- → The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy(2010)311 cited
- → Aggrecan Protects Cartilage Collagen from Proteolytic Cleavage(2003)292 cited
- → A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3(2011)272 cited
- → Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells(2006)184 cited
- → INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models(2020)